Welcome to The Menopause Digest.
The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.
I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.
Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.
This Newsletter Is Sponsored By Casa de Sante.
Menopause care is pivoting from symptom triage to full-body performance medicine, and the strategy hinges on treating movement, protein, and fuel timing as pharmacological interventions in their own right. On Menopause Matters, Let’s Talk, the “cuppa routine”—sit-to-stands and balance work every time the kettle boils—reframes exercise as an unavoidable habit rather than a scheduled chore, directly targeting the muscle and bone loss that accelerates in peri- and postmenopause. This isn’t just about mobility; it’s a fracture-prevention strategy, since hip bone density responds to simple impact loading like hopping, and balance drills cut fall risk.pmc.ncbi.nlm.nih
That same fuel-as-medicine logic shows up in sports nutrition. On Hit Play Not Pause, dietitian Kristen Arnold argues that chronic low energy availability—not aging itself—is often the real culprit behind performance plateaus, GI distress, and stubborn body composition changes in midlife athletes. Her fix is almost boringly simple: hit 3 g/kg carbs daily with tight pre- and post-workout timing, spread 1.6–2.2 g/kg protein across the day, and add a pre-sleep protein snack to blunt overnight muscle breakdown. Meanwhile, Menopause Mastery zeroes in on an unsexy but underused lever—fiber. Only about 9% of midlife women hit adequate intake, yet 25–35 g/day of fermentable fiber can lower visceral fat and improve insulin sensitivity independent of calorie counting, largely by feeding gut bacteria that produce butyrate and help clear estrogen metabolites. Think of fiber less as “roughage” and more as the switch that turns the gut into an active endocrine organ.pmc.ncbi.nlm.nih
GLP-1s are the wildcard accelerant in this metabolic story. The Plus SideZ highlights how these drugs can silence “food noise” and even blunt cravings for alcohol and nicotine, opening a window for real behavior change—but the episode’s cardiac safety flag deserves scrutiny. Broader trial data are actually more reassuring than the single patient case suggests: recent meta-analyses of GLP-1 receptor agonists show no significant increase in atrial fibrillation or ventricular arrhythmias, and some 2026 evidence even points to an 18-46% reduction in AFib risk. The clinical takeaway isn’t to fear the class, but to individualize dosing and screen at-risk patients, exactly as the Not Your Mother’s Menopause episode advises when pairing GLP-1s with resistance training to protect muscle mass during weight loss.ahajournals+2
For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:
Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss
FODMAP Digestive Enzymes – improves absorption and reduces GI side effects
Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome
Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss
Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation
All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.
Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:
HydraLift Collagen Complex – firms and smooths for youthful elasticity
Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress
Needle-Free Wrinkle Smoother – softens fine lines without irritation
Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol
Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles
Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair
Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck
Even Tone Brightening Cream – evens discoloration for radiant, balanced skin
The one-size-fits-all HRT script is dead—this week’s episodes push toward route-specific, dose-specific, and even molecule-specific personalization. The most provocative reframe comes from The DUTCH Podcast, which questions whether nightly oral micronized progesterone quietly doubles as a long-term sedative. Chronic dosing can sustain high levels of allopregnanolone, a GABA-A-active metabolite with benzodiazepine-like effects, raising real questions about cumulative cognitive impact that current research hasn’t fully answered. Their proposed fix—cyclic dosing (12-14 days/month) or a vaginal route—aims to protect the endometrium while dodging round-the-clock brain sedation, though the hosts are candid that long-term RCT data beyond 24 months simply doesn’t exist yet.dutchtest+1
That personalization push extends well past progesterone. On Not Your Mother’s Menopause, NP Shelby Sheppard argues thyroid dysfunction is routinely missed because clinicians stop at TSH instead of running a full panel, and she makes the case for expanding testosterone therapy beyond libido complaints to also address motivation and genitourinary symptoms. Vaginal estrogen, she notes, remains safe for most breast cancer survivors yet stays dramatically underprescribed. This same precision lens shows up surgically: Menopause Management with Dr. Barbie Taylor makes a sharp case that bilateral salpingo-oophorectomy—not salpingectomy alone—is the only surgery that meaningfully cuts both ovarian and breast cancer risk, and argues it should be offered opportunistically whenever a patient is already headed into the OR for something like a fibroid hysterectomy.pmc.ncbi.nlm.nih
Sexual and vulvar health is graduating from an afterthought to a specialty in its own right, with three episodes converging on the idea that pelvic pain and dysfunction are chronically under-diagnosed. On Sky Women’s Health, Dr. Chailee Moss details how hypertonic pelvic floor muscles—not hormones—often drive painful sex and urinary frequency, and how off-label Botox injections (roughly 100 units to the pubococcygeus and perineal muscles) can break the pain-spasm cycle when physical therapy alone stalls. The average patient sees five to six providers before this gets caught, a gap she frames as systemic dismissal rather than diagnostic difficulty.
The Skin Real makes a parallel case for the vulva itself: lichen sclerosus is frequently silent (up to 15% of cases are asymptomatic) yet carries roughly a 5% squamous cell carcinoma risk if untreated, making routine vulvar inspection during any skin exam a genuine cancer-prevention tool, not just a comfort measure. And on The Girlfriend Doctor, guest Connie Kean pushes intimacy redefinition and body-based practices like breathwork and pelvic visualization—soft-science territory clinicians should treat as adjunctive rather than evidence-based, but worth offering low-risk components (touch, nature exposure, mindfulness) alongside standard GSM care. Collectively, these three shows signal a commercial and clinical opening: pelvic health is becoming its own subspecialty within menopause medicine, distinct from general hormone management.
URL: Listen Here
This episode emphasizes making movement an accessible, enjoyable, and habitual part of menopause care to counter declines in muscle and bone, reduce fall risk, and improve mental health. Practical, micro‑dose strategies (strength, impact, balance, pelvic floor) and social support are highlighted, with HRT considered as a complementary tool—especially important after early menopause—for bone protection.
Reframing “exercise” as everyday “movement” improves accessibility and adherence; a balanced FABs approach—Flexibility, Aerobics, Balance, and Strength—plus social connection helps people sustain activity.
Peri- and postmenopause are critical times to prioritize movement due to declining muscle mass, bone density, and cardiovascular health; many women reduce activity then, often due to symptoms and barriers.
Start small and build habits: micro-bouts like the “cuppa routine,” sit-to-stands, stair use, dancing to music, resistance bands, and daily pelvic-floor work; address genitourinary symptoms proactively to prevent drop-out.
Strength, impact, and balance are essential for bone health: gradual resistance (including isometrics like wall squats), safe progression, and simple impact (e.g., hopping) can increase hip BMD; balance practice reduces falls and fractures.
Movement powerfully supports mood, anxiety, and sleep; combine activity with adequate protein and vitamin D, and consider HRT when indicated (especially after early menopause) as a complementary strategy for bone protection.
During menopause care, physicians should proactively identify and address activity barriers (sleep disturbance, joint pain, genitourinary symptoms) and prescribe a brief, habit-based program that integrates strength, impact, balance, and pelvic-floor training—alongside considering HRT when appropriate for bone and symptom management.
Prescribe a daily “kettle routine” and document it in the care plan: each time the kettle boils, perform 10 sit-to-stands, 10 heel raises, 30 seconds single‑leg balance per side, and a set of pelvic-floor contractions; screen for urinary leakage and, if positive, refer to pelvic health physiotherapy and review progress in 4–6 weeks.
URL: Listen Here
This episode with NP Shelby Sheppard advocates for evidence-informed, deeply personalized midlife care—reframing thyroid evaluation, using micronized progesterone postpartum tapers when appropriate, integrating GLP‑1s with protein and resistance training, and expanding the role of MHT and testosterone (including vaginal therapies) to address GSM and motivation/libido. The discussion highlights profound underuse of HRT, biopsychosocial drivers of sexual health, and the need for longer visits, better clinician education, and shared decision-making to close gaps in women’s health.
Thyroid assessment in midlife should not rely on TSH alone; correlate symptoms with a fuller panel (TSH, free T4, free T3, thyroid antibodies) and personalize therapy rather than defaulting to a single drug option.
Micronized progesterone begun at delivery and tapered over several weeks is a physiologically plausible, patient-centered option to prevent or treat postpartum depression/anxiety; use shared decision-making given limited randomized data.
GLP-1 receptor agonists can be powerful adjuncts for perimenopausal/menopausal weight and metabolic management and can reduce “food noise”; pair with adequate protein intake and resistance training and avoid aggressive dose escalation to protect muscle and bone.
Testosterone therapy in women (systemic and vaginal) can restore motivation, libido, and genitourinary function and should not be restricted to sexual complaints alone; emerging safety experience, including from transgender men on higher doses, supports thoughtful use.
Menopausal hormone therapy remains markedly underused; low-dose vaginal estrogen is safe for most, including many breast cancer survivors, and broader access requires clinician education, longer visits, and collaborative, individualized care.
A physiology-based, individualized approach—expanding beyond narrow guideline checklists (e.g., full thyroid evaluation, judicious MHT and testosterone, and selective GLP-1 use with muscle-preserving strategies)—can markedly improve quality of life and long-term risk profiles for women navigating perimenopause and menopause.
For symptomatic midlife patients with fatigue, weight/mood changes, or “normal” TSH, order TSH, free T4, free T3, and thyroid peroxidase/thyroglobulin antibodies and interpret alongside symptoms before ruling out thyroid dysfunction.
URL: Listen Here
This episode evaluates the safety and physiology of oral micronized progesterone versus vaginal progesterone in menopausal hormone therapy, highlighting concern that chronic nightly OMP may produce sustained, supraphysiologic allopregnanolone with benzodiazepine-like CNS effects in preclinical data. The hosts advocate considering cyclic dosing and/or vaginal routes to align more closely with physiology, while noting substantial evidence gaps—especially long-term RCTs on continuous OMP and cognition—and the need to individualize care and monitoring.
Oral micronized progesterone (OMP) is widely used and generally safer than synthetic progestins for endometrial protection alongside estrogen, but chronic nightly use may yield sustained supraphysiologic allopregnanolone, a GABA-A–active neurosteroid with benzodiazepine-like effects (sedation, potential cognitive impacts) in preclinical models.
Progesterone’s role extends far beyond the uterus; it has receptors in brain, bone, cardiovascular, immune, skin, and other tissues, suggesting potential benefits even after hysterectomy and arguing against viewing it solely as an endometrial protectant.
Cyclic progesterone exposure (e.g., 12–14 days/month) more closely mirrors physiology and may mitigate continuous GABAergic exposure; vaginal progesterone offers strong local endometrial effects (first-pass to uterus) with lower systemic neuroactive metabolite burden and can achieve meaningful systemic levels.
Robust, long-term randomized data on continuous OMP with estrogen (>24 months) and on cognitive outcomes are lacking; existing trials (e.g., KEEPS, ELITE) predominantly used cyclic or vaginal progesterone, underscoring important evidence gaps.
Lab testing is helpful for titrating estradiol and testosterone, but serum or urine progesterone/metabolite levels do not reliably inform adequacy of endometrial protection; dosing should follow evidence-based regimens with clinical monitoring (e.g., bleeding patterns, symptom control).
In postmenopausal hormone therapy, consider that continuous nightly OMP may drive sustained allopregnanolone exposure with potential long-term neurocognitive and metabolic downsides; a physiology-informed approach—using cyclic progesterone and/or a vaginal route with adequate estradiol—may better balance systemic benefits with safety while we await definitive human data.
For a symptomatic postmenopausal patient requiring progesterone, consider switching from continuous nightly OMP to a cyclic regimen (e.g., 200 mg OMP for 12–14 days per month) or to a vaginal progesterone preparation for the luteal segment, paired with adequate transdermal estradiol; monitor bleeding patterns and clinical response rather than relying on progesterone lab levels.
URL: Listen Here
Sports dietitian Kristen Arnold outlines a back-to-basics framework for peri/postmenopausal athletes: first meet energy availability, then optimize carbohydrate quantity/timing and protein distribution, support gut health and anti-inflammatory eating, and selectively add evidence-based supplements (e.g., creatine, beta-alanine). The guidance targets performance, symptom relief, and musculoskeletal health with practical habit-building and clinician selection tips. Note: The episode references broad evidence and mechanisms but does not cite specific studies by name for most claims.
Energy availability is foundational: chronic low energy availability (often from under-fueling) is common in peri/postmenopausal athletes and can impair endocrine function, bone health, lean mass maintenance, performance, and contribute to GI symptoms.
Prioritize carbohydrates: aim for at least 3 g/kg/day and time carbs before, during, and after training to support the endocrine response and performance; carbohydrate timing matters even if daily totals are met.
Optimize protein: target ~1.6–2.2 g/kg/day distributed across 3–5 doses, consider a small pre-sleep protein snack (leucine-rich) to reduce overnight muscle protein breakdown and support adaptation.
Support gut and symptom health via food first: emphasize prebiotic (e.g., cruciferous veg, whole grains) and probiotic foods; cruciferous vegetables (DIM) and soy isoflavones may lessen vasomotor symptoms; use probiotic supplements only when indicated with correct strain/CFUs and proper storage.
Adopt an anti-inflammatory dietary pattern and use evidence-based supplements: include omega-3–rich foods (fatty fish, flax/chia, seaweed), spices (turmeric, ginger, garlic, cinnamon), and antioxidant-rich produce; sports foods are appropriate to meet high training energy needs; consider creatine (5 g/d) and beta-alanine (chronic loading); adaptogens (ashwagandha/rhodiola) and specific black cohosh extracts may help symptoms—check for drug–herb interactions.
In active peri- and postmenopausal women, persistent GI complaints, performance plateaus, and adverse body-composition changes are frequently manifestations of chronic low energy availability—particularly inadequate carbohydrate availability/timing—so correcting fuel quantity and timing is a primary clinical lever before pursuing other interventions.
Screen for low energy availability and prescribe simple carb timing: ensure patients consume 30–60 g carbohydrate within 60 minutes pre-exercise, 30–60 g/hour during longer sessions, and a carb–protein meal/snack within 60 minutes post-exercise, while targeting a daily minimum of ≥3 g/kg carbohydrates and 1.6–2.2 g/kg protein split into 3–5 doses.
URL: Listen Here
This episode explores how GLP-1 medications may quiet food noise and dampen reward-driven cravings for alcohol and nicotine, illustrated by a patient’s experience and an addiction counselor’s perspective on pairing medication with self-love and coping strategies. It also highlights safety considerations, including potential arrhythmias at higher doses in susceptible patients, underscoring individualized risk–benefit assessment and monitoring.
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) can markedly reduce “food noise” and reward-driven cravings—including alcohol and nicotine—for some patients, creating mental space to engage in therapy and behavior change.
A patient story described immediate loss of desire to drink alcohol and smoke after starting tirzepatide, sustained appetite control even after discontinuation, and continued weight loss with lifestyle changes.
Potential cardiac safety signal: dose escalation (to higher tirzepatide doses) was associated with symptomatic tachyarrhythmias (AFib/SVT) in a patient with preexisting arrhythmias; stopping the medication reduced events.
An addiction counselor emphasized coupling pharmacotherapy with self-love, body neutrality/positivity, emotion identification, and practical coping skills; GLP-1s may blunt the reward response, but skills and community support remain essential.
Fear of starting GLP-1s is common (change, injections, stigma); clinicians should address risk–benefit, set expectations, screen for cardiac history, and coordinate care (e.g., cardiology) when indicated.
GLP-1 therapies can attenuate mesolimbic, reward-driven cravings that underlie binge eating and some substance use behaviors, offering a clinically meaningful window to do behavioral work—yet clinicians should screen for and monitor tachyarrhythmias (especially with dose escalation and in those with preexisting arrhythmias) and tailor therapy accordingly.
Before initiating or increasing a GLP-1 RA, obtain a focused cardiac history (AFib/SVT, palpitations), consider a baseline ECG for at‑risk patients, counsel that cravings may diminish and pair treatment with behavioral/mental health support, and monitor heart rate and symptoms—collaborating with cardiology and using the lowest effective dose when needed.
URL: Listen Here
This episode reframes carbohydrates by emphasizing dietary fiber as the key missing nutrient in menopause, explaining how fiber-driven microbiome activity lowers visceral fat, improves insulin sensitivity, and optimizes estrogen clearance and detox pathways. The host argues these benefits are largely independent of calorie counts and are best achieved through diverse whole-food fibers rather than supplements alone. Specific study details are discussed at a high level without full citations in the episode.
Only about 9% of midlife U.S. women meet daily fiber needs; targeting 25–35 g/day of mostly fermentable fiber is critical for metabolic health in menopause.
Adequate fiber reduces visceral fat and improves insulin sensitivity independent of calorie intake and exercise by slowing gastric emptying, blunting postprandial glucose, and promoting SCFA (butyrate)-mediated GLP-1/PYY signaling.
Low-fiber, high-protein/low-carb patterns can shift the microbiome toward proteolytic fermentation, generating toxic metabolites (e.g., ammonia, hydrogen sulfide, cadaverine), impairing gut barrier function, increasing systemic inflammation, and disrupting estrogen clearance via elevated beta-glucuronidase.
Fiber supports estrogen metabolism and detoxification by binding bile acids, improving transit (reducing reabsorption during constipation), and upregulating phase 2 detox enzymes (e.g., via butyrate effects on glutathione pathways).
Whole-food fiber sources (fruits, vegetables, legumes, nuts/seeds, whole grains, cooked-and-cooled starches) outperform fiber supplements alone; gradually increasing diverse fiber across meals is practical and better tolerated.
For peri- and postmenopausal women, prioritizing diverse, fermentable dietary fiber is a potent, non-pharmacologic lever to reduce visceral adiposity and insulin resistance while supporting estrogen metabolism and detoxification—often outperforming macronutrient restriction alone.
Track fiber for one week (e.g., with Cronometer) and progressively raise intake to 25–35 g/day by: adding 1/2–1 cup berries at breakfast, 1/2 cup legumes to lunch salads, a side salad plus a 1/2 cup cooked-and-cooled potato/rice or root vegetables at dinner, and optionally 5 g soluble fiber (e.g., psyllium or partially hydrolyzed guar gum) with water; increase slowly to minimize GI symptoms.
URL: Listen Here
This episode explores how women can reignite energy and sexual vitality in midlife by pairing reframed intimacy with “energy” practices such as Reiki-inspired self-holding, pelvic-focused visualization, grounding, and gratitude-based states. It also introduces self-muscle testing to personalize choices. Claims reflect complementary and spiritual perspectives and are not universally evidence-based; clinicians can adapt low-risk components (breath, touch, nature exposure, mindfulness) alongside standard medical care.
Postmenopausal sexuality can remain vibrant; intimacy often deepens when couples expand definitions beyond penetrative sex (e.g., skin-to-skin contact, emotional connection).
Simple energy-focused practices (self-holding over the pelvis/root, breathwork, visualizing a warm red light in the “pelvic bowl,” grounding in nature) are proposed to rekindle vitality, mood, and libido.
Unprocessed emotions may manifest as somatic or “energetic” blocks; gentle techniques (e.g., counterclockwise hand motions over the chest/throat, gratitude and compassion practices) are used to release grief and heartache.
“True-for-you” self-muscle testing (using the body as a pendulum) is used by some to personalize daily choices (supplements, foods, medications), fostering body awareness though it is not a standard medical tool.
Higher-coherence states (love, gratitude) and time in nature are linked to improved autonomic balance/HRV in emerging literature; the episode frames this within broader consciousness models (e.g., Hawkins’ Map of Consciousness).
For many midlife and postmenopausal patients, reframing sexual health to include non-coital intimacy and incorporating low-risk, sensory and energy-centered practices (breath, touch, nature exposure) may alleviate distress and help restore desire and connection, complementing conventional care for GSM, mood, and sleep.
Teach interested patients a 5–10 minute nightly “pelvic bowl” practice: lie comfortably, place hands at the inguinal creases, breathe slowly through the nose, and visualize a warm red light filling the pelvis; encourage daily nature time when possible. Reassess energy, mood, and sexual interest after 2–4 weeks.
URL: Listen Here
This episode demystifies vulvar anatomy and normalizes evaluation of vulvar skin, outlining common dermatoses and cancers seen in this area. It emphasizes accurate diagnosis and long-term management of lichen sclerosus with super-potent topical steroids, gentle skin care practices, appropriate use of biopsy, and collaboration with gynecology—particularly in postmenopausal patients and those with skin of color. Note: Some statistics (e.g., ~15% asymptomatic LS; ~5% SCC risk when untreated) were discussed without formal citation in the transcript.
Vulvar skin is just skin—and it develops common inflammatory dermatoses (eczema, psoriasis) as well as serious conditions (lichen sclerosus, lichen planus, extramammary Paget disease, squamous cell carcinoma, melanoma); full-body skin exams should routinely include the vulva.
Lichen sclerosus (LS) often presents with pruritus more than pain and can show fissures/erosions; up to ~15% may be asymptomatic, so absence of symptoms does not exclude disease.
First-line LS therapy is a super-potent topical corticosteroid (e.g., clobetasol) for induction followed by lifelong maintenance (typically 2–3 times/week) to prevent scarring and reduce squamous cell carcinoma risk (~5% when untreated).
Biopsy is warranted for new, firm, indurated, bleeding, or nonhealing areas and for rashes unresponsive to appropriate therapy; vulvar SCC may arise via HPV-driven or chronic lichenoid (LS/LP) pathways.
Gentle care only: avoid douching, fragrances, and many marketed ‘vulvar’ products (e.g., Vagisil can trigger allergic contact dermatitis); prefer warm water cleansing and bland barriers (petrolatum, zinc oxide). In skin of color, erythema may appear violaceous and LS can have vitiligoid pigment loss; address psychosocial impact and collaborate with gynecology when vaginal involvement or GSM coexists.
Lichen sclerosus is underrecognized and requires high-potency topical steroid induction followed by lifelong maintenance to prevent scarring and lower squamous cell carcinoma risk—making routine, normalized vulvar examination and counseling essential in dermatologic care.
Make vulvar and perianal inspection a standard, non-optional part of every total body skin exam and document findings.
URL: Listen Here
This episode explains how hypertonic pelvic floor dysfunction drives painful sex and related urinary symptoms, and details an off-label interventional option—pelvic floor botulinum toxin injections—used alongside pelvic floor physical therapy and dilators. The discussion covers pathophysiology, selection, technique, dosing, safety, limitations of Botox, and strategies to avoid medical gaslighting, while noting an ongoing randomized trial to strengthen the evidence base.
Hypertonic pelvic floor muscles are a common, under-recognized cause of painful sex, tampon intolerance, and urinary frequency; reflexive guarding shortens muscles, reduces perfusion, and perpetuates a pain–spasm cycle.
Routine speculum exams often miss pelvic floor hypertonicity; patients frequently see 5–6 providers and experience dismissal before diagnosis—targeted pelvic floor examination (digital palpation, Q-tip mapping) is essential.
First-line care includes pelvic floor physical therapy, muscle relaxants, dilators, and education; botulinum neurotoxin injections are off-label but can rapidly reduce tone and accelerate progress when conservative therapy is insufficient.
A practical injection approach often starts with ~100 units targeting pubococcygeus and transverse perineal muscles, with reassessment at 4–6 weeks for a possible second series; use topical anesthetic ± nitrous oxide, and counsel about transient symptom flare and rare flatus/stool leakage.
Botox treats muscle hypertonicity but not conditions like lichen sclerosus, hormonal vestibulodynia, or pudendal neuralgia; best outcomes occur when combined with pelvic floor PT and structured dilator work; high-quality efficacy data are forthcoming (ongoing placebo-controlled trial).
For insertional dyspareunia, explicitly examine for pelvic floor hypertonicity and manage with a multimodal plan—pelvic floor PT and dilators as foundation, with selective off-label botulinum toxin injections to levator ani and transverse perineal muscles to disrupt the pain–guarding cycle and restore function.
In patients with penetration pain or tampon intolerance, perform a targeted pelvic floor exam (Q-tip vestibular mapping and digital palpation of levator ani/transverse perineal muscles); if hypertonicity persists despite skilled pelvic floor PT, discuss coordinated off-label botulinum toxin treatment (~100 units initially with possible second session at 4–6 weeks) while continuing PT and dilator therapy, and set expectations about transient flares and rare incontinence risks.
URL: Listen Here
This episode reviews preventive gynecologic surgery strategies—elective, opportunistic, and risk-reducing—in the context of epithelial ovarian cancer’s low incidence but high lethality and poor detectability. It argues that BSO offers the most reliable risk reduction (and also reduces breast cancer risk), urges skepticism toward salpingectomy-alone strategies based on limited evidence, and encourages thorough, patient-directed shared decision-making, especially when surgery is already planned for another indication.
Epithelial ovarian cancer (EOC) has a relatively low lifetime incidence for average-risk women (~1 in 78; ~1.4%), but it lacks effective early detection, is typically diagnosed late, responds incompletely to treatment, and carries poor survival—making prevention a central consideration.
Preventive gynecologic surgeries can be framed as elective, opportunistic, or risk-reducing; decisions should weigh surgical risks against cancer risk, patient goals, and timing (e.g., adding procedures when surgery is already indicated).
Bilateral salpingo-oophorectomy (BSO) is presented as the only definitive surgical method to substantially reduce EOC risk and it also lowers breast cancer risk, whereas salpingectomy alone (removal of tubes only) may leave substantial residual risk.
When benign gynecologic surgery is already indicated (e.g., hysterectomy for fibroids), adding opportunistic risk-reducing BSO may add minimal incremental operative risk and should be explicitly discussed and aligned with patient preferences.
The episode critiques the trend toward salpingectomy-alone prevention, citing limitations of supporting studies (tubal-origin focus, short follow-up, and comparator mismatches), and emphasizes critical appraisal plus shared decision-making, including planning for menopausal hormone therapy after oophorectomy.
For average-risk women, the combination of poor screening, late-stage detection, and high mortality of epithelial ovarian cancer warrants proactive, shared decision-making about opportunistic risk-reducing BSO at the time of indicated gynecologic surgery rather than salpingectomy alone, with anticipatory guidance for post-oophorectomy menopausal management.
Before benign gynecologic surgeries in peri- or postmenopausal patients who have completed childbearing, use a standardized preoperative counseling checklist that covers absolute EOC risk, the lack of effective screening, comparative risk reduction of salpingectomy vs BSO, effects on breast cancer risk, surgical/anesthetic risks, and a plan for menopausal symptom and long-term health management (e.g., estrogen therapy) if oophorectomy is chosen.
Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:
Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website
Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:
Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.
Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.
It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.
👉 Deploy your Medical AI Chatbot today and take control of your health narrative
Managing menopause isn’t about “getting through it”—it’s about doing it strategically. The Menopause Premium Program is a 16-week, high-touch protocol designed for high-performing women who demand more than quick fixes. With board-certified specialists, evidence-based hormone and non-hormonal options, and proactive risk reduction, this program helps restore clarity, stabilize sleep, and safeguard long-term health. If brain fog, disrupted nights, or unpredictable weight shifts are holding you back, this is your opportunity to take control with the same precision you bring to your career.
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.